Polycythemia Vera Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major polycythemia vera markets reached a value of US$ 17.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 68.5 Billion by 2034, exhibiting a growth rate (CAGR) of 13.44% during 2024-2034.
The polycythemia vera market has been comprehensively analyzed in IMARC's new report titled "Polycythemia Vera Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Polycythemia vera is a rare, chronic blood disorder characterized by an overproduction of white blood cells (WBCs), red blood cells (RBCs), and platelets in the bone marrow. This condition can lead to an increase in blood volume and thickness, which can further cause a range of complications, including heart attack and brain stroke. The common indications of the ailment include itchiness, especially after a warm bath, a feeling of fullness, pain in the left upper abdomen, unusual bleeding from the nose or gums, painful swelling of the big toe, shortness of breath, numbness, tingling, or burning in the hands, feet, legs, or arms, etc. In some cases, individuals might also experience vague symptoms, such as fatigue, headache, dizziness, blurred vision, etc. The diagnosis of polycythemia vera typically requires a combination of clinical features, a detailed medical history, and a physical exam. Numerous blood tests involving the measurement of hematocrit, iron-rich protein, platelets, etc., are further utilized to confirm a diagnosis. Additionally, the healthcare provider may perform bone marrow aspiration or biopsy to assess the bone marrow and its functioning.
The increasing cases of gene mutations that affect the development of blood cells in the bone marrow are primarily driving the polycythemia vera market. In addition to this, the rising prevalence of several associated risk factors, including advancing age, obesity, a history of blood clots, smoking, diabetes, pregnancy, etc., are also bolstering the market growth. Furthermore, the escalating adoption of effective medications, such as anti-platelets, antihistamines, selective serotonin reuptake inhibitors, etc., which provide symptom relief and boost the overall health of patients, is acting as another significant growth-inducing factor. Additionally, numerous key players are focusing on the better understanding of cellular pathways and gene mutations involved in the pathogenesis of polycythemia vera to launch more effective treatment alternatives. This, in turn, is also creating a positive outlook for the market. Moreover, the emerging popularity of ropeginterferon alfa-2b, since it helps the immune system fight against the overactive bone marrow cells associated with the disease, thereby preventing the overproduction of red blood cells, is expected to drive the polycythemia vera market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the polycythemia vera market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for polycythemia vera and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the polycythemia vera market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the polycythemia vera market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the polycythemia vera market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current polycythemia vera marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the polycythemia vera market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the polycythemia vera market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the polycythemia vera market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of polycythemia vera across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of polycythemia vera by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of polycythemia vera by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with polycythemia vera across the seven major markets?
What is the size of the polycythemia vera patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of polycythemia vera?
What will be the growth rate of patients across the seven major markets?
Polycythemia Vera: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for polycythemia vera drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the polycythemia vera market?
What are the key regulatory events related to the polycythemia vera market?
What is the structure of clinical trial landscape by status related to the polycythemia vera market?
What is the structure of clinical trial landscape by phase related to the polycythemia vera market?
What is the structure of clinical trial landscape by route of administration related to the polycythemia vera market?
The polycythemia vera market has been comprehensively analyzed in IMARC's new report titled "Polycythemia Vera Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Polycythemia vera is a rare, chronic blood disorder characterized by an overproduction of white blood cells (WBCs), red blood cells (RBCs), and platelets in the bone marrow. This condition can lead to an increase in blood volume and thickness, which can further cause a range of complications, including heart attack and brain stroke. The common indications of the ailment include itchiness, especially after a warm bath, a feeling of fullness, pain in the left upper abdomen, unusual bleeding from the nose or gums, painful swelling of the big toe, shortness of breath, numbness, tingling, or burning in the hands, feet, legs, or arms, etc. In some cases, individuals might also experience vague symptoms, such as fatigue, headache, dizziness, blurred vision, etc. The diagnosis of polycythemia vera typically requires a combination of clinical features, a detailed medical history, and a physical exam. Numerous blood tests involving the measurement of hematocrit, iron-rich protein, platelets, etc., are further utilized to confirm a diagnosis. Additionally, the healthcare provider may perform bone marrow aspiration or biopsy to assess the bone marrow and its functioning.
The increasing cases of gene mutations that affect the development of blood cells in the bone marrow are primarily driving the polycythemia vera market. In addition to this, the rising prevalence of several associated risk factors, including advancing age, obesity, a history of blood clots, smoking, diabetes, pregnancy, etc., are also bolstering the market growth. Furthermore, the escalating adoption of effective medications, such as anti-platelets, antihistamines, selective serotonin reuptake inhibitors, etc., which provide symptom relief and boost the overall health of patients, is acting as another significant growth-inducing factor. Additionally, numerous key players are focusing on the better understanding of cellular pathways and gene mutations involved in the pathogenesis of polycythemia vera to launch more effective treatment alternatives. This, in turn, is also creating a positive outlook for the market. Moreover, the emerging popularity of ropeginterferon alfa-2b, since it helps the immune system fight against the overactive bone marrow cells associated with the disease, thereby preventing the overproduction of red blood cells, is expected to drive the polycythemia vera market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the polycythemia vera market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for polycythemia vera and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the polycythemia vera market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the polycythemia vera market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the polycythemia vera market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current polycythemia vera marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the polycythemia vera market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the polycythemia vera market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the polycythemia vera market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of polycythemia vera across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of polycythemia vera by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of polycythemia vera by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with polycythemia vera across the seven major markets?
What is the size of the polycythemia vera patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of polycythemia vera?
What will be the growth rate of patients across the seven major markets?
Polycythemia Vera: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for polycythemia vera drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the polycythemia vera market?
What are the key regulatory events related to the polycythemia vera market?
What is the structure of clinical trial landscape by status related to the polycythemia vera market?
What is the structure of clinical trial landscape by phase related to the polycythemia vera market?
What is the structure of clinical trial landscape by route of administration related to the polycythemia vera market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POLYCYTHEMIA VERA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POLYCYTHEMIA VERA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POLYCYTHEMIA VERA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 POLYCYTHEMIA VERA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POLYCYTHEMIA VERA - UNMET NEEDS
10 POLYCYTHEMIA VERA - KEY ENDPOINTS OF TREATMENT
11 POLYCYTHEMIA VERA - MARKETED PRODUCTS
11.1 List of Polycythemia Vera Marketed Drugs Across the Top 7 Markets
11.1.1 Besremi (Ropeginterferon alfa 2b) - AOP Orphan Pharmaceuticals/PharmaEssentia Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Jakafi (Ruxolitinib) - Incyte Corporation/Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 POLYCYTHEMIA VERA - PIPELINE DRUGS
12.1 List of Polycythemia Vera Pipeline Drugs Across the Top 7 Markets
12.1.1 Givinostat - Italfarmaco
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 PTG300 - Protagonist Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Bomedemstat - Imago BioSciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Sapablursen - Ionis Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 PPMXT003 - Perseus Proteomics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POLYCYTHEMIA VERA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POLYCYTHEMIA VERA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POLYCYTHEMIA VERA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Polycythemia Vera - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Polycythemia Vera - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Polycythemia Vera - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Polycythemia Vera - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Polycythemia Vera - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Polycythemia Vera - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Polycythemia Vera - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Polycythemia Vera - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Polycythemia Vera - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Polycythemia Vera - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Polycythemia Vera - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Polycythemia Vera - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Polycythemia Vera - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Polycythemia Vera - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Polycythemia Vera - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Polycythemia Vera - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Polycythemia Vera - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Polycythemia Vera - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Polycythemia Vera - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Polycythemia Vera - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Polycythemia Vera - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Polycythemia Vera - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Polycythemia Vera - Access and Reimbursement Overview
16 POLYCYTHEMIA VERA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POLYCYTHEMIA VERA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POLYCYTHEMIA VERA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POLYCYTHEMIA VERA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POLYCYTHEMIA VERA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POLYCYTHEMIA VERA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 POLYCYTHEMIA VERA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POLYCYTHEMIA VERA - UNMET NEEDS
10 POLYCYTHEMIA VERA - KEY ENDPOINTS OF TREATMENT
11 POLYCYTHEMIA VERA - MARKETED PRODUCTS
11.1 List of Polycythemia Vera Marketed Drugs Across the Top 7 Markets
11.1.1 Besremi (Ropeginterferon alfa 2b) - AOP Orphan Pharmaceuticals/PharmaEssentia Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Jakafi (Ruxolitinib) - Incyte Corporation/Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 POLYCYTHEMIA VERA - PIPELINE DRUGS
12.1 List of Polycythemia Vera Pipeline Drugs Across the Top 7 Markets
12.1.1 Givinostat - Italfarmaco
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 PTG300 - Protagonist Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Bomedemstat - Imago BioSciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Sapablursen - Ionis Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 PPMXT003 - Perseus Proteomics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POLYCYTHEMIA VERA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POLYCYTHEMIA VERA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POLYCYTHEMIA VERA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Polycythemia Vera - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Polycythemia Vera - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Polycythemia Vera - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Polycythemia Vera - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Polycythemia Vera - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Polycythemia Vera - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Polycythemia Vera - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Polycythemia Vera - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Polycythemia Vera - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Polycythemia Vera - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Polycythemia Vera - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Polycythemia Vera - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Polycythemia Vera - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Polycythemia Vera - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Polycythemia Vera - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Polycythemia Vera - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Polycythemia Vera - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Polycythemia Vera - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Polycythemia Vera - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Polycythemia Vera - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Polycythemia Vera - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Polycythemia Vera - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Polycythemia Vera - Access and Reimbursement Overview
16 POLYCYTHEMIA VERA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POLYCYTHEMIA VERA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POLYCYTHEMIA VERA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
